journal article·2020-10-28

HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo

Guanping He, Xiaoyu Pan, Xiao Liu, Ye Zhu, Yunlong Ma, Chuanchao Du, Xiaoguang Liu, Chuanbin Mao

ACS Applied Materials & Interfaces· Volume 12· Issue 43
Publisher page

Abstract

Although ZnO nanoparticles (NPs) can kill human osteosarcoma cells, the underlying upstream regulatory mechanisms remain unclear. Since hypoxia inducible factor-1α (HIF-1α) regulates the tumor microenvironment, here we explored the interplay between HIF-1α regulation and mitophagy in ZnO NP-induced osteosarcoma inhibition both in vivo and in vitro. We found that ZnO NPs upregulated HIF-1α protein levels when they killed four common human osteosarcoma cell lines. This finding was consistent with our observations that additional HIF-1α upregulation by a hypoxia inducer CoCl2 or under a 1% hypoxia environment enhanced NP-induced cell death, but concurrent HIF-1α suppression by a hypoxia inhibitor YC-1 or HIF-1α siRNA inhibited NP-induced cell death. We discovered an interplay between HIF-1α and the autophagy–Zn2+–reactive oxygen species (ROS)–autophagy cycle axis and revealed that NP-induced cancer cell killing followed a HIF-1α-BNIP3-LC3B-mediated mitophagy pathway. We confirmed that NP-upregulated HIF-1α protein expression was attributed to prolyl hydroxylase inhibition by both ROS and Zn2+. In addition, the in vivo assay confirmed the therapeutic effectiveness and safety of ZnO NPs on a nude mice osteosarcoma model. Collectively, our findings clarified the upstream regulatory mechanism of autophagy induced by the NPs and further demonstrated their antitumor ability in vivo. This work provides new targets and strategies for enhancing NP-based osteosarcoma treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China

Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States

The Center for Pain Medicine, Peking University Third Hospital, No. 49, North Garden Street, Haidian District, Beijing 100191, China

Funding

Natural Science Foundation of Beijing Municipality · University of Oklahoma · National Natural Science Foundation of China

References (39)

Show source-provided references
1. 10.1038/nrc246810.1038/nrc2468 ↗
2. 10.1126/science.aaf440510.1126/science.aaf4405 ↗
3. 10.2147/OTT.S15820610.2147/OTT.S158206 ↗
4. 10.1038/nrc70410.1038/nrc704 ↗
5. 10.1016/j.jdermsci.2018.03.01010.1016/j.jdermsci.2018.03.010 ↗
6. 10.1186/s12989-016-0163-310.1186/s12989-016-0163-3 ↗
7. 10.1371/journal.pone.001504810.1371/journal.pone.0015048 ↗
8. 10.26355/eurrev_201902_1699310.26355/eurrev_201902_16993 ↗
9. 10.1016/j.biocel.2014.02.01610.1016/j.biocel.2014.02.016 ↗
10. 10.1038/nature0845510.1038/nature08455 ↗
11. 10.1016/S1474-4422(18)30238-210.1016/S1474-4422(18)30238-2 ↗
12. 10.1016/j.cell.2014.02.04910.1016/j.cell.2014.02.049 ↗
13. 10.1002/adhm.20180033210.1002/adhm.201800332 ↗
14. 10.5772/6343710.5772/63437 ↗
15. 10.1517/17425247.2010.50256010.1517/17425247.2010.502560 ↗
16. 10.1007/978-1-4419-0284-9_410.1007/978-1-4419-0284-9_4 ↗
17. 10.1016/j.mayocp.2012.01.01510.1016/j.mayocp.2012.01.015 ↗
18. 10.1056/NEJM19990729341050710.1056/NEJM199907293410507 ↗
19. 10.1016/S1470-2045(17)30346-710.1016/S1470-2045(17)30346-7 ↗
20. 10.3322/caac.2116610.3322/caac.21166 ↗
21. 10.1038/nrclinonc.2015.6310.1038/nrclinonc.2015.63 ↗
22. 10.1016/j.ceb.2009.11.01510.1016/j.ceb.2009.11.015 ↗
23. 10.1093/toxsci/kfn25110.1093/toxsci/kfn251 ↗
24. 10.1016/j.taap.2005.11.00610.1016/j.taap.2005.11.006 ↗
25. 10.1039/C6NR08188F10.1039/C6NR08188F ↗
26. 10.1016/j.drup.2011.03.00110.1016/j.drup.2011.03.001 ↗
27. 10.18632/oncotarget.2389310.18632/oncotarget.23893 ↗
28. 10.1021/es202417t10.1021/es202417t ↗
29. 10.1136/jcp.2003.01503210.1136/jcp.2003.015032 ↗
30. 10.1038/3504000910.1038/35040009 ↗
31. 10.1023/A:102066892385210.1023/A:1020668923852 ↗
32. 10.1080/15548627.2016.119275310.1080/15548627.2016.1192753 ↗
33. 10.1158/0008-5472.CAN-10-015710.1158/0008-5472.CAN-10-0157 ↗
34. 10.1038/cddis.2017.37110.1038/cddis.2017.371 ↗
35. 10.1007/s00018-019-03122-410.1007/s00018-019-03122-4 ↗
36. 10.1016/j.devcel.2017.02.01610.1016/j.devcel.2017.02.016 ↗
37. 10.1074/jbc.M112.39934510.1074/jbc.M112.399345 ↗
38. 10.1007/s00432-012-1256-510.1007/s00432-012-1256-5 ↗
39. 10.3892/or.2015.401110.3892/or.2015.4011 ↗